THLD 2.73 Threshold Pharmaceuticals $THLD Hit a 52 week low of 2.58 Currently at 2.73 +0.02 +0.74% With a day low of 2.58 and a total volume of 665,700.
THLD Threshold Pharmaceuticals Recent Headline News
Threshold Pharmaceuticals Announces New Phase 1/2 Data on TH-302 in Multiple Myeloma to Be Presented at the 2014 ASH Annual Meeting
Marketwired - Thu Nov 06, 8:06AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that new data from an ongoing Phase 1/2 trial evaluating TH-302 and low-dose dexamethasone with or without the proteasome inhibitor bortezomib (Velcade(R)) in patients with relapsed/refractory multiple myeloma will be presented in a poster at the 56th Annual Meeting of the American Society of Hematology (ASH) held in San Francisco, California, from December 6 - 9, 2014 (Abstract #2142).
THLD: 2.73 (+0.02)
Threshold Pharmaceuticals posts 3Q loss
Automated Insights - Mon Nov 03, 6:06AM CST
SOUTH SAN FRANCISCO, Calif. (AP) _ Threshold Pharmaceuticals Inc. (THLD) on Monday reported a third-quarter loss of $7.7 million.
THLD: 2.73 (+0.02)
Threshold Pharmaceuticals Announces New Phase 1/2 Data on TH-302 in Glioblastoma to be Presented at the 2014 SNO Annual Meeting
Marketwired - Mon Nov 03, 6:05AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that new data from an investigator-sponsored Phase 1/2 trial evaluating the combination of TH-302 and Avastin(R) (bevacizumab) in patients with bevacizumab-refractory recurrent glioblastoma will be presented in two posters at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO) held in Miami, Florida, from November 13-16, 2014.
THLD: 2.73 (+0.02)
Threshold Pharmaceuticals Reports Third Quarter 2014 Financial and Operational Results
Marketwired - Mon Nov 03, 6:01AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today reported financial results for the third quarter 2014. Revenue for the third quarter ended September 30, 2014 was $3.7 million. The operating loss for the third quarter ended September 30, 2014 was $7.6 million. The net loss for the third quarter ended September 30, 2014 was $7.7 million, which included the operating loss of $7.6 million and non-cash expense of $0.3 million related to the changes in fair value of the Company's outstanding and exercised warrants and was classified as other income (expense). As of September 30, 2014, Threshold had $68.5 million in cash, cash equivalents and marketable securities, with no debt outstanding.
THLD: 2.73 (+0.02)
Threshold Pharmaceuticals' Partner Merck KGaA, Darmstadt, Germany, Completes Target Enrollment in the TH-302 Phase 3 MAESTRO Study in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Marketwired - Mon Nov 03, 5:59AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today announced that Threshold's partner Merck KGaA, Darmstadt, Germany, through its biopharmaceutical division, has completed target enrollment of 660 patients in the global Phase 3 MAESTRO (MetastAtic or unrESectable pancreaTic adenocarcinoma) study assessing the efficacy and safety of TH-302 in combination with gemcitabine in patients with previously untreated, locally advanced unresectable or metastatic pancreatic adenocarcinoma. Threshold has a global license and co-development agreement with Merck KGaA, Darmstadt, Germany for TH-302, which includes an option for Threshold to co-commercialize in the U.S.
THLD: 2.73 (+0.02)
Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma
PR Newswire - Wed Oct 22, 7:45AM CDT
Investor-Edge has initiated coverage on the following equities: Amicus Therapeutics Inc. (NASDAQ: FOLD), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Threshold Pharmaceuticals Inc. (NASDAQ: THLD), Idera Pharmaceuticals Inc. (NASDAQ: IDRA), and Merrimack Pharmaceuticals Inc. (NASDAQ: MACK). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, October 21, 2014, the NASDAQ Composite ended at 4,419.48, up 2.40%, the Dow Jones Industrial Average advanced 1.31%, to finish the day at 16,614.81, and the S&P 500 closed at 1,941.28, up 1.96%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 735.36, up 2.65%, with the index also advancing 5.56% in the previous three trading sessions. Register for your complimentary reports on these five stocks at:
MACK: 8.70 (-0.07), PGNX: 5.37 (+0.76), IDRA: 2.43 (-0.06), THLD: 2.73 (+0.02), FOLD: 5.72 (-0.16)
Investors look to Lighten Up on Shares of Threshold Pharmaceuticals, Shares Down 6.1% (THLD)
Comtex SmarTrend(R) - Fri Oct 10, 12:42PM CDT
Threshold Pharmaceuticals (NASDAQ:THLD) is one of today's worst performing low-priced stocks, down 6.1% to $2.91 on 1.2x average daily volume. Threshold Pharmaceuticals has traded 1.2 million shares thus far today, vs. average volume of 997,000 shares per day. The stock has underperformed the Dow (-6.1% to the Dow's 0.1%) and underperformed the S&P 500 (-6.1% to the S&P's -0.2%) during today's trading.
THLD: 2.73 (+0.02)
Commit To Buy Threshold Pharmaceuticals At $2.50, Earn 12.5% Annualized Using Options
StockOptionsChannel.com - Fri Sep 26, 10:36AM CDT
Investors eyeing a purchase of Threshold Pharmaceuticals Inc shares, but cautious about paying the going market price of $3.79/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting...
THLD: 2.73 (+0.02)
Hot Stock: Threshold Pharmaceuticals, Shares Drop 7.0% (THLD)
Comtex SmarTrend(R) - Mon Sep 22, 10:08AM CDT
Threshold Pharmaceuticals (NASDAQ:THLD) is one of today's worst performing low-priced stocks, down 7.0% to $4.16 on 2.0x average daily volume. Thus far today, Threshold Pharmaceuticals has traded 1.6 million shares, vs. average volume of 792,000 shares per day. The stock has underperformed the Dow (-7.0% to the Dow's -0.4%) and underperformed the S&P 500 (-7.0% to the S&P's -0.7%) during today's trading.
THLD: 2.73 (+0.02)
Threshold Pharmaceuticals Announces Its Phase 3 Trial of TH-302 in Patients With Advanced Soft Tissue Sarcoma Will Continue as Planned Following Protocol-Specified Interim Analysis
Marketwire - Mon Sep 22, 7:02AM CDT
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that the Independent Data Monitoring Committee (IDMC) has completed the planned interim efficacy and safety analyses of unblinded data for the Company's pivotal Phase 3 clinical trial of TH-302 in combination with doxorubicin versus doxorubicin alone in patients with locally advanced unresectable or metastatic soft tissue sarcoma (STS). Based on their analyses, which included an assessment of both benefit and risk, the IDMC recommended that the trial should continue as planned to its natural conclusion.
THLD: 2.73 (+0.02)
These 7 States Have the Highest Rates of Pancreatic Cancer
Sean Williams, The Motley Fool - Motley Fool - Sat Sep 13, 11:17AM CDT
Source: National Cancer Institute via Wikimedia Commons . The word "cancer" is scary regardless of the type, but few types of cancer are as lethal as pancreatic cancer. Based on estimates from the American Cancer Society in 2013, an estimated...
OMED: 20.19 (-0.02), NLNK: 32.15 (-2.54), THLD: 2.73 (+0.02), LLY: 66.60 (-0.36), CELG: 106.45 (-0.69)
Uptrend Call Working As Threshold Pharmaceuticals Stock Rises 19.5% (THLD)
Comtex SmarTrend(R) - Thu Sep 11, 4:57PM CDT
SmarTrend identified an Uptrend for Threshold Pharmaceuticals (NASDAQ:THLD) on June 9th, 2014 at $4.21. In approximately 3 months, Threshold Pharmaceuticals has returned 19.48% as of today's recent price of $5.03.
THLD: 2.73 (+0.02)
Nasdaq stocks posting largest volume increases
AP - Wed Sep 10, 5:16PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
NETE: 1.42 (+0.15), HBNK: 19.91 (+0.15), LUNA: 1.43 (+0.05), BKYF: 47.24 (-0.14), OTIV: 2.67 (+0.10), THLD: 2.73 (+0.02), PLMT: 15.87 (+0.37), GCBC: 27.72 (unch), THTI: 1.52 (-0.06), MTSL: 1.21 (-0.07)
Market Maker Surveillance Report. THLD, GIGA, BKYF, RADA, MGAM, BNNY, Winning Stocks With Lowest Price Friction For Monday, September 8th 2014
M2 - Tue Sep 09, 3:15AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 4710 companies with "abnormal" market making, 2110 companies with positive Friction Factors and 2786 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Monday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Threshold Pharmaceuticals Inc (NASDAQ:THLD), Giga Tronics Inc (NASDAQ:GIGA), Bank Of Kentucky Financial Corp (NASDAQ:BKYF), Rada Electronic Industries Ltd (NASDAQ:RADA), Multimedia Games Holding Company Inc (NASDAQ:MGAM), Annies's Inc (NYSE:BNNY). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
BKYF: 47.24 (-0.14), RADA: 2.69 (-0.12), BNNY: 45.97 (-0.01), MGAM: 35.23 (+0.15), THLD: 2.73 (+0.02), GIGA: 1.75 (+0.05)
Traders Get Bullish on Shares of Threshold Pharmaceuticals, Shares Up 5.2% (THLD)
Comtex SmarTrend(R) - Mon Sep 08, 10:09AM CDT
Threshold Pharmaceuticals (NASDAQ:THLD) is one of today's best performing low-priced stocks, up 5.2% to $4.17 on 1.8x average daily volume. Thus far today, Threshold Pharmaceuticals has traded 612,000 shares, vs. average volume of 332,000 shares per day. The stock has outperformed the Dow (5.2% to the Dow's -0.1%) and outperformed the S&P 500 (5.2% to the S&P's -0.2%) during today's trading.
THLD: 2.73 (+0.02)
Threshold Pharmaceuticals Announces Presentation and Webcast at the Rodman & Renshaw 16th Annual Global Investment Conference
Marketwire - Tue Sep 02, 6:01AM CDT
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Rodman & Renshaw 16th Annual Global Investment Conference on Tuesday, September 9, 2014, at 10:50 a.m. Eastern Time.
THLD: 2.73 (+0.02)
Biotech Stock Mailbag: Threshold, Galena, CytRx
at The Street - Fri Aug 22, 7:48AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
CYTR: 2.87 (-0.06), THLD: 2.73 (+0.02), GALE: 1.95 (-0.09)
5 Stocks Ready for Breakouts
at The Street - Mon Aug 11, 8:17AM CDT
These stocks look poised to break out and trade higher from current levels.
UA: 66.98 (+0.70), TWOU: 17.89 (+0.02), THLD: 2.73 (+0.02), HIMX: 7.81 (+0.04), ANR: 2.91 (+0.39), XOMA: 3.81 (-0.31)
Threshold Pharmaceuticals Reports Second Quarter 2014 Financial and Operational Results
Marketwire - Fri Aug 01, 6:01AM CDT
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today reported financial results for the second quarter 2014. Revenue for the second quarter ended June 30, 2014 was $3.7 million. The operating loss for the second quarter ended June 30, 2014 was $7.5 million. The net loss for the second quarter ended June 30, 2014 was $0.8 million, which included the operating loss of $7.5 million and non-cash income of $6.7 million related to the changes in fair value of the Company's outstanding warrants and was classified as other income (expense). As of June 30, 2014, Threshold had $75.2 million in cash, cash equivalents and marketable securities, with no debt outstanding.
THLD: 2.73 (+0.02)
4 Biotech Stocks Under $10 to Trade for Breakouts
at The Street - Fri Aug 01, 6:00AM CDT
These under-$10 biotech stocks are within range of triggering breakout trades.
CRMD: 1.69 (-0.07), ACRX: 6.04 (+0.41), THLD: 2.73 (+0.02), OHRP: 7.07 (-0.07)
THLD Threshold Pharmaceuticals Recent Headline News
Threshold Pharmaceuticals Announces New Phase 1/2 Data on TH-302 in Multiple Myeloma to Be Presented at the 2014 ASH Annual Meeting
Marketwired - Thu Nov 06, 8:06AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that new data from an ongoing Phase 1/2 trial evaluating TH-302 and low-dose dexamethasone with or without the proteasome inhibitor bortezomib (Velcade(R)) in patients with relapsed/refractory multiple myeloma will be presented in a poster at the 56th Annual Meeting of the American Society of Hematology (ASH) held in San Francisco, California, from December 6 - 9, 2014 (Abstract #2142).
THLD: 2.73 (+0.02)
Threshold Pharmaceuticals posts 3Q loss
Automated Insights - Mon Nov 03, 6:06AM CST
SOUTH SAN FRANCISCO, Calif. (AP) _ Threshold Pharmaceuticals Inc. (THLD) on Monday reported a third-quarter loss of $7.7 million.
THLD: 2.73 (+0.02)
Threshold Pharmaceuticals Announces New Phase 1/2 Data on TH-302 in Glioblastoma to be Presented at the 2014 SNO Annual Meeting
Marketwired - Mon Nov 03, 6:05AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that new data from an investigator-sponsored Phase 1/2 trial evaluating the combination of TH-302 and Avastin(R) (bevacizumab) in patients with bevacizumab-refractory recurrent glioblastoma will be presented in two posters at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO) held in Miami, Florida, from November 13-16, 2014.
THLD: 2.73 (+0.02)
Threshold Pharmaceuticals Reports Third Quarter 2014 Financial and Operational Results
Marketwired - Mon Nov 03, 6:01AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today reported financial results for the third quarter 2014. Revenue for the third quarter ended September 30, 2014 was $3.7 million. The operating loss for the third quarter ended September 30, 2014 was $7.6 million. The net loss for the third quarter ended September 30, 2014 was $7.7 million, which included the operating loss of $7.6 million and non-cash expense of $0.3 million related to the changes in fair value of the Company's outstanding and exercised warrants and was classified as other income (expense). As of September 30, 2014, Threshold had $68.5 million in cash, cash equivalents and marketable securities, with no debt outstanding.
THLD: 2.73 (+0.02)
Threshold Pharmaceuticals' Partner Merck KGaA, Darmstadt, Germany, Completes Target Enrollment in the TH-302 Phase 3 MAESTRO Study in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Marketwired - Mon Nov 03, 5:59AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today announced that Threshold's partner Merck KGaA, Darmstadt, Germany, through its biopharmaceutical division, has completed target enrollment of 660 patients in the global Phase 3 MAESTRO (MetastAtic or unrESectable pancreaTic adenocarcinoma) study assessing the efficacy and safety of TH-302 in combination with gemcitabine in patients with previously untreated, locally advanced unresectable or metastatic pancreatic adenocarcinoma. Threshold has a global license and co-development agreement with Merck KGaA, Darmstadt, Germany for TH-302, which includes an option for Threshold to co-commercialize in the U.S.
THLD: 2.73 (+0.02)
Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma
PR Newswire - Wed Oct 22, 7:45AM CDT
Investor-Edge has initiated coverage on the following equities: Amicus Therapeutics Inc. (NASDAQ: FOLD), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Threshold Pharmaceuticals Inc. (NASDAQ: THLD), Idera Pharmaceuticals Inc. (NASDAQ: IDRA), and Merrimack Pharmaceuticals Inc. (NASDAQ: MACK). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, October 21, 2014, the NASDAQ Composite ended at 4,419.48, up 2.40%, the Dow Jones Industrial Average advanced 1.31%, to finish the day at 16,614.81, and the S&P 500 closed at 1,941.28, up 1.96%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 735.36, up 2.65%, with the index also advancing 5.56% in the previous three trading sessions. Register for your complimentary reports on these five stocks at:
MACK: 8.70 (-0.07), PGNX: 5.37 (+0.76), IDRA: 2.43 (-0.06), THLD: 2.73 (+0.02), FOLD: 5.72 (-0.16)
Investors look to Lighten Up on Shares of Threshold Pharmaceuticals, Shares Down 6.1% (THLD)
Comtex SmarTrend(R) - Fri Oct 10, 12:42PM CDT
Threshold Pharmaceuticals (NASDAQ:THLD) is one of today's worst performing low-priced stocks, down 6.1% to $2.91 on 1.2x average daily volume. Threshold Pharmaceuticals has traded 1.2 million shares thus far today, vs. average volume of 997,000 shares per day. The stock has underperformed the Dow (-6.1% to the Dow's 0.1%) and underperformed the S&P 500 (-6.1% to the S&P's -0.2%) during today's trading.
THLD: 2.73 (+0.02)
Commit To Buy Threshold Pharmaceuticals At $2.50, Earn 12.5% Annualized Using Options
StockOptionsChannel.com - Fri Sep 26, 10:36AM CDT
Investors eyeing a purchase of Threshold Pharmaceuticals Inc shares, but cautious about paying the going market price of $3.79/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting...
THLD: 2.73 (+0.02)
Hot Stock: Threshold Pharmaceuticals, Shares Drop 7.0% (THLD)
Comtex SmarTrend(R) - Mon Sep 22, 10:08AM CDT
Threshold Pharmaceuticals (NASDAQ:THLD) is one of today's worst performing low-priced stocks, down 7.0% to $4.16 on 2.0x average daily volume. Thus far today, Threshold Pharmaceuticals has traded 1.6 million shares, vs. average volume of 792,000 shares per day. The stock has underperformed the Dow (-7.0% to the Dow's -0.4%) and underperformed the S&P 500 (-7.0% to the S&P's -0.7%) during today's trading.
THLD: 2.73 (+0.02)
Threshold Pharmaceuticals Announces Its Phase 3 Trial of TH-302 in Patients With Advanced Soft Tissue Sarcoma Will Continue as Planned Following Protocol-Specified Interim Analysis
Marketwire - Mon Sep 22, 7:02AM CDT
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that the Independent Data Monitoring Committee (IDMC) has completed the planned interim efficacy and safety analyses of unblinded data for the Company's pivotal Phase 3 clinical trial of TH-302 in combination with doxorubicin versus doxorubicin alone in patients with locally advanced unresectable or metastatic soft tissue sarcoma (STS). Based on their analyses, which included an assessment of both benefit and risk, the IDMC recommended that the trial should continue as planned to its natural conclusion.
THLD: 2.73 (+0.02)
These 7 States Have the Highest Rates of Pancreatic Cancer
Sean Williams, The Motley Fool - Motley Fool - Sat Sep 13, 11:17AM CDT
Source: National Cancer Institute via Wikimedia Commons . The word "cancer" is scary regardless of the type, but few types of cancer are as lethal as pancreatic cancer. Based on estimates from the American Cancer Society in 2013, an estimated...
OMED: 20.19 (-0.02), NLNK: 32.15 (-2.54), THLD: 2.73 (+0.02), LLY: 66.60 (-0.36), CELG: 106.45 (-0.69)
Uptrend Call Working As Threshold Pharmaceuticals Stock Rises 19.5% (THLD)
Comtex SmarTrend(R) - Thu Sep 11, 4:57PM CDT
SmarTrend identified an Uptrend for Threshold Pharmaceuticals (NASDAQ:THLD) on June 9th, 2014 at $4.21. In approximately 3 months, Threshold Pharmaceuticals has returned 19.48% as of today's recent price of $5.03.
THLD: 2.73 (+0.02)
Nasdaq stocks posting largest volume increases
AP - Wed Sep 10, 5:16PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
NETE: 1.42 (+0.15), HBNK: 19.91 (+0.15), LUNA: 1.43 (+0.05), BKYF: 47.24 (-0.14), OTIV: 2.67 (+0.10), THLD: 2.73 (+0.02), PLMT: 15.87 (+0.37), GCBC: 27.72 (unch), THTI: 1.52 (-0.06), MTSL: 1.21 (-0.07)
Market Maker Surveillance Report. THLD, GIGA, BKYF, RADA, MGAM, BNNY, Winning Stocks With Lowest Price Friction For Monday, September 8th 2014
M2 - Tue Sep 09, 3:15AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 4710 companies with "abnormal" market making, 2110 companies with positive Friction Factors and 2786 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Monday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Threshold Pharmaceuticals Inc (NASDAQ:THLD), Giga Tronics Inc (NASDAQ:GIGA), Bank Of Kentucky Financial Corp (NASDAQ:BKYF), Rada Electronic Industries Ltd (NASDAQ:RADA), Multimedia Games Holding Company Inc (NASDAQ:MGAM), Annies's Inc (NYSE:BNNY). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
BKYF: 47.24 (-0.14), RADA: 2.69 (-0.12), BNNY: 45.97 (-0.01), MGAM: 35.23 (+0.15), THLD: 2.73 (+0.02), GIGA: 1.75 (+0.05)
Traders Get Bullish on Shares of Threshold Pharmaceuticals, Shares Up 5.2% (THLD)
Comtex SmarTrend(R) - Mon Sep 08, 10:09AM CDT
Threshold Pharmaceuticals (NASDAQ:THLD) is one of today's best performing low-priced stocks, up 5.2% to $4.17 on 1.8x average daily volume. Thus far today, Threshold Pharmaceuticals has traded 612,000 shares, vs. average volume of 332,000 shares per day. The stock has outperformed the Dow (5.2% to the Dow's -0.1%) and outperformed the S&P 500 (5.2% to the S&P's -0.2%) during today's trading.
THLD: 2.73 (+0.02)
Threshold Pharmaceuticals Announces Presentation and Webcast at the Rodman & Renshaw 16th Annual Global Investment Conference
Marketwire - Tue Sep 02, 6:01AM CDT
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Rodman & Renshaw 16th Annual Global Investment Conference on Tuesday, September 9, 2014, at 10:50 a.m. Eastern Time.
THLD: 2.73 (+0.02)
Biotech Stock Mailbag: Threshold, Galena, CytRx
at The Street - Fri Aug 22, 7:48AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
CYTR: 2.87 (-0.06), THLD: 2.73 (+0.02), GALE: 1.95 (-0.09)
5 Stocks Ready for Breakouts
at The Street - Mon Aug 11, 8:17AM CDT
These stocks look poised to break out and trade higher from current levels.
UA: 66.98 (+0.70), TWOU: 17.89 (+0.02), THLD: 2.73 (+0.02), HIMX: 7.81 (+0.04), ANR: 2.91 (+0.39), XOMA: 3.81 (-0.31)
Threshold Pharmaceuticals Reports Second Quarter 2014 Financial and Operational Results
Marketwire - Fri Aug 01, 6:01AM CDT
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today reported financial results for the second quarter 2014. Revenue for the second quarter ended June 30, 2014 was $3.7 million. The operating loss for the second quarter ended June 30, 2014 was $7.5 million. The net loss for the second quarter ended June 30, 2014 was $0.8 million, which included the operating loss of $7.5 million and non-cash income of $6.7 million related to the changes in fair value of the Company's outstanding warrants and was classified as other income (expense). As of June 30, 2014, Threshold had $75.2 million in cash, cash equivalents and marketable securities, with no debt outstanding.
THLD: 2.73 (+0.02)
4 Biotech Stocks Under $10 to Trade for Breakouts
at The Street - Fri Aug 01, 6:00AM CDT
These under-$10 biotech stocks are within range of triggering breakout trades.
CRMD: 1.69 (-0.07), ACRX: 6.04 (+0.41), THLD: 2.73 (+0.02), OHRP: 7.07 (-0.07)
